Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on...
-
New York City, NY, March 23, 2026 (GLOBE NEWSWIRE) -- As demand for Bitcoin casino no deposit bonuses continues to rise in 2026, players are becoming more selective about which offers are...
-
A French public limited company (société anonyme) with share capital of €1,455,643,262.50Registered office: 1973, boulevard de la Défense, F-92000 NanterreRegistration number 552 037 806 RCS...
-
Ilkka Oyj Pörssitiedote 23.3.2026, klo 16.35 KUTSU ILKKA OYJ:N VARSINAISEEN YHTIÖKOKOUKSEENIlkka Oyj:n osakkeenomistajat kutsutaan varsinaiseen yhtiökokoukseen, joka pidetään torstaina...
-
Ilkka Oyj Pörssitiedote 23.3.2026, klo 16.15ILKKA OYJ:N PALKITSEMIS- JA NIMITYSVALIOKUNNAN EHDOTUKSET YHTIÖKOKOUKSELLE JA HALLINTONEUVOSTON LAUSUNTO OSAKKEENOMISTAJIEN EHDOTUKSESTA...
-
London, UK, March 23, 2026 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (NASDAQ: RCT) ("RedCloud" or the "Company"), the technology company building AI infrastructure for global trade today declared...
-
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with...
-
Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three...
-
DANBURY, Conn., March 23, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (NASDAQ: FCEL) is taking significant steps toward meeting the speed of delivery and surging demand of data centers for...
-
Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus.Le candidat vaccin a été bien...